Your shopping cart is currently empty

Y502-2304 is a c-MycG-quadruplex stabilizer that exhibits potent antiproliferative activity in multiple myeloma (MM) cells. It downregulates c-Myc mRNA and protein expression and induces apoptosis in MM cells, as characterized by increased γH2AX levels, elevated reactive oxygen species (ROS) production, and mitochondrial dysfunction. Additionally, Y502-2304 significantly inhibits tumor growth in xenograft MM models and is useful for studying multiple myeloma.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Y502-2304 is a c-MycG-quadruplex stabilizer that exhibits potent antiproliferative activity in multiple myeloma (MM) cells. It downregulates c-Myc mRNA and protein expression and induces apoptosis in MM cells, as characterized by increased γH2AX levels, elevated reactive oxygen species (ROS) production, and mitochondrial dysfunction. Additionally, Y502-2304 significantly inhibits tumor growth in xenograft MM models and is useful for studying multiple myeloma. |
| Molecular Weight | 369.36 |
| Formula | C16H11N5O4S |
| Cas No. | 741278-95-5 |
| Smiles | O=C(OC)C=1SC=2N=CN3N=C(N=C3C2C1C)C=4C=CC(=CC4)N(=O)=O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.